Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Creative Commons License

Petrylak D. P., de Wit R., Chi K. N., Drakaki A., Sternberg C. N., Nishiyama H., ...Daha Fazla

LANCET, cilt.390, sa.10109, ss.2266-2277, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 390 Sayı: 10109
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1016/s0140-6736(17)32365-6
  • Dergi Adı: LANCET
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.2266-2277
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Background Few treatments with a distinct mechanism of action are available for patients with platinum-refractory advanced or metastatic urothelial carcinoma. We assessed the efficacy and safety of treatment with docetaxel plus either ramucirumab-a human IgG1 VEGFR-2 antagonist-or placebo in this patient population.